Brief: Revive Therapeutics announces rights offering to fund clinical development of Bucillamine
16/05/2016 12:00
May 16 (Reuters) - Revive Therapeutics Ltd RVV.V
* Revive announces rights offering to fund the clinical
development of Bucillamine for the treatment of Cystinuria
Source text for Eikon: ID:nCCN1bckfY
Further company coverage: RVV.V
(Bengaluru Newsroom: +1-646-223-8780)
Recent news on Revive Therapeutics
See all newsBrief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Announces Closing Of Second Tranche Of Private Placement
Brief: Revive Therapeutics Nears Completion Of Key Nerve Agent Countermeasure Study With Canadian Department Of National Defence
Brief: Revive Therapeutics Provides Update On Research Study Evaluating Bucillamine For Nerve Agent Exposure